Inspection Response Record · Worked sample
One GMP decision. Five deliverables. This is what you receive.
Built from a real CAPA effectiveness closure. Every submission generates:
- ✓ Authorization Record
- ✓ Executive Brief
- ✓ Defensibility Analysis
- ✓ Response Kit
- ✓ Investigator Challenge Guide
The scenario is fictitious; the format is exactly what you receive for your own decision. Nothing is invented — every line is built from the inputs you submit. Gaps are flagged, not hidden.
See how the package is built
If every CAPA your team closed on an effectiveness window in the last 24 months were pulled tomorrow, how many have an independent reviewer on record — not just the closing signature?
Not sure whether your organization has decision-defensibility gaps? Assess Your Decision Defensibility →
The decision under inspection
A quality director closed a CAPA after a 90-day effectiveness window, concluding a recurring environmental-monitoring excursion had been corrected. Months later, an investigator asks the question the CAPA record can't answer on its own:
“How did you determine CAPA-2025-0118 was effective? What evidence supported closure, and on what basis was it closed when it was?”
Here is the package that answers it — rendered exactly as it's delivered.
This package reconstructs and evaluates one authorization decision. Each tab answers a different inspection question.
CAPA-2025-0118 · originating deviation DEV-2025-0042. This is the source record. The Executive Brief, Evidence, Remediation, and FDA Challenge tabs are generated from it.
§01 Investigator Question
How did you determine CAPA-2025-0118 was effective? What evidence supported closure, and on what basis was it closed when it was?
§02 Authorization Summary
P. Trubl, Director Quality Systems & CAPA, authorized closure of CAPA-2025-0118 on 12-AUG-2025, concluding that the corrective action — revised procedure SOP-EM-318 R04 and analyst retraining — effectively reduced recurrence risk for the environmental-monitoring excursion originating in DEV-2025-0042.
§03 Evidence Reviewed
- Environmental-monitoring trend — 90 days, zero excursions [primary]
- Analyst retraining records — roster requalified [supporting]
- SOP-EM-318 R04 — procedural control revised [supporting]
- Internal audit observation at day 65 — compliant execution [corroborating]
§04 Risk Evaluation
Known risk: recurrence of the environmental-monitoring excursion and associated contamination risk in the aseptic area. Residual risk: low — zero recurrence across a 90-day window spanning more than two monitoring cycles. Patient and product impact: none observed. Residual risk was accepted because three convergent evidence streams supported the effectiveness conclusion and routine controls continue post-closure.
§05 Alternatives Considered
Extending the verification window — rejected; 90 days already spanned more than two full monitoring cycles. Deferring closure pending the next scheduled audit — rejected; the day-65 audit had already confirmed compliant execution. Closure with continued routine monitoring was selected as the disposition consistent with the evidence.
§06 Authorization Reasoning
The effectiveness conclusion rested on convergent evidence rather than absence of recurrence alone: a 90-day EM trend with zero excursions, completed retraining of the analyst roster, the revised procedure in force, and an independent audit observation confirming the procedure was executed as written. The window was defined prospectively and covered the variability under which the original excursion occurred. On the weight of that convergence, closure was justified at the time it was authorized.
§07 Regulatory Alignment
21 CFR 211.192 (production record review and CAPA); 21 CFR 211.100 (written procedures; deviations); 21 CFR 211.113 (control of microbiological contamination); ICH Q10 (pharmaceutical quality system). Effectiveness closure is recognized where a defined verification window, convergent evidence, and a documented effectiveness conclusion support the determination.
§08 Residual Exposure Statement
Remaining uncertainty: theoretical recurrence under conditions not represented in the window — new analysts added post-window, equipment maintenance, or a change in monitoring media. Monitoring commitment: daily EM logging and weekly QA review continue as routine GMP beyond closure.
§09 Reconstruction Prevention Statement
This record was generated to document the authorization reasoning contemporaneously with the operational decision in order to prevent post-inspection reconstruction of release justification.
§10 Known Limitations
Closure was authorized by a single authority; an independent effectiveness review is added in the Response Kit above. The verification-window justification and the exclusion of alternative recurrence causes were not present in the original record; both are addressed in the Response Kit. Assumes the environmental-monitoring method remained in its validated state across the window.
This package reflects structured inputs only. The named decision owner is the authorizing party. ComplianceWorxs is the recording medium, not the authorizer. Scenario and identifiers are fictitious.
A single individual authorized closure. No independent reviewer is recorded, so an investigator reopens the effectiveness conclusion itself — and every other CAPA closed the same way under the same signature comes under review with it.
Decision
CAPA Effectiveness Closure — CAPA-2025-0118, originating deviation DEV-2025-0042.
Authorization Basis
90 days of environmental monitoring with zero recurrence, completed analyst retraining, and a revised procedure (SOP-EM-318 R04) in force.
Inspection Exposure
The closure is substantively sound but relies on a single authority, asserts the verification window without justifying it, and does not show alternative causes were ruled out. An investigator can reopen the closure on any of the three.
Documentation Action Before Inspection
Add an independent reviewer statement, a window-justification statement, and an alternative-causes-excluded statement — all three are written and ready to paste in the Remediation tab.
Critical Exposure
- A single individual authorized closure. No independent reviewer is recorded — the finding an investigator writes up is not this one CAPA, it's every closure that authorizer has signed alone.
Reconstruction Risk
- The 90-day verification window is stated but not justified. An investigator can ask why 90 days was sufficient for this failure mode, and the record cannot answer.
- Alternative recurrence pathways — procedural drift, analyst turnover, seasonal variation — are not documented as considered and ruled out.
| Evidence | Source | Date | Supports |
|---|---|---|---|
| EM trend — 90 days, zero excursions | EM-DAILY | 14-MAY → 12-AUG | Demonstrates no recurrence across the window |
| Analyst retraining records | TRAIN-EM | 02-MAY | Corrective action implemented and verified |
| SOP-EM-318 R04 | QMS-SOP | 28-APR | Procedural control revised |
| Internal audit observation | AUDIT-2025-031 | 18-JUL | Independent confirmation of compliance at day 65 |
The exact language that closes each gap — written from your record, ready to paste.
No independent reviewer recorded
Location
Paste into: CAPA Closure Record — Effectiveness Review · Signatory: independent reviewer
Template
Verification window not justified
Location
Paste into: CAPA Closure Record — Effectiveness Window · Signatory: P. Trubl, Director QS & CAPA
Template
Alternative causes not excluded
Location
Paste into: CAPA Closure Record — Recurrence Analysis · Signatory: P. Trubl, Director QS & CAPA
Template
FDA Question
How did you determine CAPA-2025-0118 was effective, and on what basis was it closed when it was?
Best supported response
Closure was authorized by P. Trubl, Director Quality Systems & CAPA, on 12-AUG-2025, after a 90-day verification window in which environmental monitoring recorded zero excursions in the affected aseptic area. Effectiveness rested on three convergent streams — the EM trend, completed analyst retraining, and revised procedure SOP-EM-318 R04 — with an independent audit observation at day 65 confirming compliance.
FDA Question
Why was a 90-day window sufficient to conclude the corrective action was effective?
Best supported response
Ninety days spanned more than two full environmental-monitoring cycles and thirteen weekly QA reviews, covering the analyst-workload and shift variability present when the original excursion occurred. The window was defined prospectively, before implementation, and was long enough to surface recurrence had the action failed.
FDA Question
What alternative explanations for the absence of recurrence did you consider and rule out?
Best supported response
Procedural drift was ruled out by a day-65 internal audit observing compliant execution; analyst turnover was ruled out because the retrained roster stayed intact; and facility or seasonal variation was ruled out by the absence of excursions in adjacent classified areas over the same period. Absence of recurrence alone was not treated as proof of effectiveness.
Preserve the reasoning before it has to be reconstructed.
You answer structured questions about one consequential decision. The system flags the gaps. The completed IRR is delivered as a usable record — not a promise, the record itself.
When the original reasoning is not preserved, the organization has to rebuild the evidence reviewed, alternatives considered, risk judgment, decision reasoning, and authorization — often months or years later, under inspection pressure.
Create an IRR — $497 →Authorization Record · Executive Brief · Defensibility Analysis · Response Kit · Investigator Challenge Guide
Not sure whether your organization has decision-defensibility gaps? Assess Your Decision Defensibility →